A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
BGB-A317-A3055-101
Phase 1 other active
Quick answer
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors for Advanced or metastatic solid tumors is a Phase 1 program (other) at BeiGene Ireland Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeiGene Ireland Ltd
- Indication
- Advanced or metastatic solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active